Donal J. Sexton

Donal J. Sexton

Auto-generated profile, based on publicly available information

Donal J. Sexton

Renal Unit, St James Hospital, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
DSDonal J. Sexton
Donal J. Sexton
MCMark Canney
Mark Canney
MOMatthew D. L. O’cOnnell
Matthew D. L. O’cOnnell
PMPatrick Vincent Moore
Patrick Vincent Moore
MLMark A Little
Mark A Little
RKRose-Anne Kenny
Rose-Anne Kenny
The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treating adults 75 years of age or older with hypertension to reach a systolic blood pressure target of less than 120 mm Hg compared with a systolic blood pressure target of less than 140 mm Hg reduced the numbers of cardiovascular events and death without a significant increase in the number of injurious falls or syncope.1 However, prior to the adoption of an intensive strategy to lower systolic blood pressure in the oldest segment of the population, it is prudent to determine if individuals meeting inclusion criteria for SPRINT outside the clinical trial context are similar to trial participants, especially with regard to risk for adverse outcomes. We used The Irish Longitudinal Study on Ageing2,3 (TILDA) to compare baseline rates of injurious falls and syncope in community-dwelling older adults with the rates in the standard care group of SPRINT.

1 July 2018 in Kidney International Reports
Verified
Journal Article
Open access
DSDonal J. Sexton
Donal J. Sexton
DFDeclan G. de Freitas
Declan G. de Freitas
MLMark A Little
Mark A Little
TMTomas McHugh
Tomas McHugh
CMColm Magee
Colm Magee
COConall M. O’sEaghdha
Conall M. O’sEaghdha
We report 2 cases of apixaban use as prophylaxis against thromboembolism in the nephrotic syndrome (NS), and review the existing literature on direct-acting oral anticoagulant (DOAC) use in this scenario. Our cases appear to be the first reported use of apixaban as prophylaxis against thromboembolism in NS. We report our systematic review of the existing literature on direct-acting oral anticoagulant (DOAC) use in NS, and discuss theoretical issues relevant to their therapeutic use in this clinical scenario. We searched electronic databases such as OVID, EMBASE, PubMed, and CENTRAL, DARE. The search to identify studies and the application of inclusion and exclusion criteria was performed in duplicate independently. We identified 1 pilot randomized study, 3 case reports, and 3 conference proceedings abstracts relating to DOAC use in NS. These reports all pertain to the treatment of clinically evident thrombosis in NS with rivaroxaban, edoxaban, and dabigatran rather than prophylaxis against thrombosis. Although the existing literature on DOAC use in NS is limited, initial preliminary experience appears promising.

2 June 2022
Verified
Book Chapter
Closed access
PDF file
AKAli Karaali
Ali Karaali
RDRozenn Dahyot
Rozenn Dahyot
DSDonal J. Sexton
Donal J. Sexton

16 July 2019 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
JOJames Paul O'Neill
James Paul O'Neill
DSDonal J. Sexton
Donal J. Sexton
EOEamonn O'Leary
Eamonn O'Leary
POPatrick O'Kelly
Patrick O'Kelly
SMSusan Murray
Susan Murray
PCPeter J. Conlon
Peter J. Conlon

21 August 2024 in Kidney360
Verified
Journal Article
Open access
CJConor Judge
Conor Judge
FKFinn Krewer
Finn Krewer
MOMartin J. O'DOnnell
Martin J. O'DOnnell
LKLisa Kiely
Lisa Kiely
DSDonal Sexton
Donal Sexton
BTBryan Tripp
Bryan Tripp
Traditional medical artificial intelligence models that are approved for clinical use restrict themselves to single-modal data (e.g., images only), limiting their applicability in the complex, multimodal environment of medical diagnosis and treatment. Multimodal transformer models in health care can effectively process and interpret diverse data forms, such as text, images, and structured data. They have demonstrated impressive performance on standard benchmarks, like United States Medical Licensing Examination question banks, and continue to improve with scale. However, the adoption of these advanced artificial intelligence models is not without challenges. While multimodal deep learning models like transformers offer promising advancements in health care, their integration requires careful consideration of the accompanying ethical and environmental challenges.

27 February 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CSCaragh P. Stapleton
Caragh P. Stapleton
AHAndreas Heinzel
Andreas Heinzel
WGWeihua Guan
Weihua Guan
PMPeter J. van der Most
Peter J. van der Most
JSJessica van Setten
Jessica van Setten
TNThe International Genetics and Translational Research in Transplantation Network
The International Genetics and Translational Research in Transplantation Network
Genetic variation across the human leukocyte antigen loci is known to influence renal-transplant outcome. However, the impact of genetic variation beyond the human leukocyte antigen loci is less clear. We tested the association of common genetic variation and clinical characteristics, from both the donor and recipient, with posttransplant eGFR at different time-points, out to 5 years posttransplantation. We conducted GWAS meta-analyses across 10 844 donors and recipients from five European ancestry cohorts. We also analyzed the impact of polygenic risk scores (PRS), calculated using genetic variants associated with nontransplant eGFR, on posttransplant eGFR. PRS calculated using the recipient genotype alone, as well as combined donor and recipient genotypes were significantly associated with eGFR at 1-year posttransplant. Thirty-two percent of the variability in eGFR at 1-year posttransplant was explained by our model containing clinical covariates (including weights for death/graft-failure), principal components and combined donor-recipient PRS, with 0.3% contributed by the PRS. No individual genetic variant was significantly associated with eGFR posttransplant in the GWAS. This is the first study to examine PRS, composed of variants that impact kidney function in the general population, in a posttransplant context. Despite PRS being a significant predictor of eGFR posttransplant, the effect size of common genetic factors is limited compared to clinical variables.